Aquablation Therapy

Aquablation therapy is the only BPH treatment clinically proven to provide long-term symptom relief while preserving sexual function and continence in prostates of all shapes and sizes.1,2

Missed the Webinar?

In case you missed it, check back soon to watch the recorded webinar on-demand.

When
June 26, 2024
3:00 PM and 6:00 PM CST

Presented by
Dr. Gerald Park, Kansas City Urology Care

Featuring
Patients who have experienced relief from lower urinary tract symptoms due to an enlarged prostate through Aquablation therapy.

What to Expect
  • Expert insights from Dr. Park on Aquablation Therapy
  • Real patient stories, including a former Kansas City Chiefs football player
  • Q&A session where you can ask questions
  • Assistance in finding a urologist near you who performs Aquablation therapy

Aquablation therapy is the first and only ultrasound guided, robotic assisted, heat-free waterjet for the treatment of BPH.
DID YOU KNOW?

83% of patients are not willing to sacrifice sexual function for symptom relief with surgery?3


Men should not have to choose between symptom relief and sexual function.
  • Efficacy Matters
  • Sexual Function Matters
  • Durability Matters
  • Urinary Continence Matters
IN THE NEWS

Fox News Feature

Fox News medical contributor Dr. Marc Siegel discusses how BPH affects millions of men across the U.S. to kick off Men’s Health Month.
FEATURED SPEAKER

Dr. Gerald Park

Dr. Gerald Park is a board-certified urologist. Dr. Park completed his Urologic training at the University of Kansas Medical Center, where he served as chief resident and was awarded the Pfizer Scholar Award in Urology. Prior to that he received his B.A. from Rice University and his M.D. from the University of Texas Medical Branch at Galveston. He has presented scientific research at the American Urological Association national meeting and has published in the Journal of Urology.

Dr. Park has pioneered BPH treatments by being the first surgeon to bring Aquablation therapy to the Kansas City Area.

Side image
References
1. Gilling PJ et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol. 2022;29(1):10960-10968.
2. Bhojani et al. Aquablation therapy in large prostates (80-150 mL) for lower urinary tract symptoms due to benign prostatic hyperplasia: final WATER II 5-Year clinical trial results. 2023 Journal of Urology.
3. Data on file at PROCEPT BioRobotics.

Safety and Risk Information
Risk & Safety Information: All surgical treatments have inherent and associated side effects. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about the potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Aquablation therapy is performed by urologists.
Patients should talk to their doctor to determine if Aquablation therapy is right for them. Patients and doctors should review the potential benefits and limitations of treatment together.

© 2024 PROCEPT BioRobotics Corporation.
All rights reserved. AQUABLATION, AQUABEAM, and PROCEPT BioRobotics are the registered trademarks of PROCEPT BioRobotics Corporation.
ML0575.A